Autopsy report · NCT03403205

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

“Sponsor decision to terminate the program”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 5 years 4 months before it stopped.
• 214 participants enrolled.
• Results were posted on the registry 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Alexion Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Wilson Disease

Interventions

ALXN1840; SoC Therapy

Participants

214

Sites

56

Countries

Australia, Austria, Canada, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Japan, New Zealand and more

Trials that died the same way

• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (85% match in meaning)
• Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
  “Sponsor decision to terminate study.” (85% match in meaning)
• Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
  “Sponsor requested termination” (83% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (82% match in meaning)
• The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
  “Business decision by sponsor to terminate the study” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.